8th Annual Antifibrotic Drug Development Summit
The landmark FDA approval of the first MASH therapeutic, the orphan drug designation for systemic sclerosis trials, and the rapid advancement of IPF treatments through clinical phases have ignited a transformative era in fibrosis research. Now more than ever experts are doubling down on fibrosis.
As the focus on innovative therapies intensifies, there is a pressing need for cutting-edge strategies that can overcome preclinical and clinical challenges has never been more critical. With that, Iโm delighted to announce the return of the ๐๐ป๐๐ถ๐ณ๐ถ๐ฏ๐ฟ๐ผ๐๐ถ๐ฐ ๐๐ฟ๐๐ด ๐๐ฒ๐๐ฒ๐น๐ผ๐ฝ๐บ๐ฒ๐ป๐ ๐ฆ๐๐บ๐บ๐ถ๐ for its ๐ด๐๐ต ๐๐ฒ๐ฎ๐ฟ as the fibrosis community's premier event, uniting industry experts and key opinion leaders across Pulmonology, Hepatology, Rheumatology, Nephrology, Cardiology, and Gastroenterology.
Gathering decision makers to share cross fibrosis insights on innovative strategies to navigate the shared fibrosis challenges from discovery to novel targets, preclinical models, biomarkers, and early-stage clinical trials. Gain exclusive insights and strategies to apply to your own research accelerating the development of truly transformative, disease-modifying, โantifibroticโ therapeutics.
Whether focusing on ๐๐ฃ๐, ๐ ๐๐ฆ๐, ๐๐๐๐๐ฒ๐บ๐ถ๐ฐ ๐๐ฐ๐น๐ฒ๐ฟ๐ผ๐๐ถ๐, ๐ธ๐ถ๐ฑ๐ป๐ฒ๐ ๐ณ๐ถ๐ฏ๐ฟ๐ผ๐๐ถ๐, ๐ฐ๐ฎ๐ฟ๐ฑ๐ถ๐ฎ๐ฐ ๐ณ๐ถ๐ฏ๐ฟ๐ผ๐๐ถ๐, ๐ณ๐ถ๐ฏ๐ฟ๐ผ๐๐ถ๐ป๐ด ๐๐๐ or ๐ฎ๐ป๐ผ๐๐ต๐ฒ๐ฟ, this summit is your collective forum to propel innovative and efficacious antifibrotic therapeutics to patients in need.
Join us at the 8th AFDD Summit to be part of the conversation, share your insights, and discover the innovations that are transforming fibrosis treatment.
Find out here
